Anti-TNFα therapy in systemic autoimmune and/or inflammatory diseases;Traitements anti-TNFα dans les maladies auto-immunes et/ou inflammatoires systémiques

Presse Medicale

Volumn 38, Issue 5, 2009, Pages 761-773

  Régent, Alexis ^a   Mouthon, Luc ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; NEUTROPHIL CYTOPLASMIC ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ADALIMUMAB; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT ONSET STILL DISEASE; AMYLOIDOSIS; AORTA ARCH SYNDROME; AUTOIMMUNE DISEASE; BEHCET DISEASE; DERMATOMYOSITIS; DRUG INDICATION; HUMAN; INFLAMMATORY DISEASE; MYOSITIS; POLYMYOSITIS; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SCLERODERMA; SHORT SURVEY; SJOEGREN SYNDROME; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; TEMPORAL ARTERITIS; UVEITIS; VASCULITIS; ARTICLE; DRUG ANTAGONISM; INFLAMMATION;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; AUTOIMMUNE DISEASES; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; METHOTREXATE; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 65449166389     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2009.02.006     Document Type: Short Survey

References (103)

1. Present D.H., Rutgeerts P., Targan S., Hanauer S.B., Mayer L., van Hogezand R.A., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340 (1999) 1398-1405
2. Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., Olson A., Johanns J., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 (2005) 2462-2476
3. Jarnerot G., Hertervig E., Friis-Liby I., Blomquist L., Karlen P., Granno C., et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis :a randomized, placebo-controlled study. Gastroenterology 128 (2005) 1805-1811
4. Claudepierre P., Wendling D., and Cohen J.D. Anti-TNF alpha dans le traitement du rhumatisme psoriasique. Presse Med 35 (2006) 647-655
5. Chaudhari U., Romano P., Mulcahy L.D., Dooley L.T., Baker D.G., and Gottlieb A.B. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis : a randomised trial. Lancet 357 (2001) 1842-1847
6. Jover J.A., Hernandez-Garcia C., Morado I.C., Vargas E., Banares A., and Fernandez-Gutierrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone : a randomized, double-blind, placebo-controlled trial. Ann Intern Med 134 (2001) 106-114
7. Spiera R.F., Mitnick H.J., Kupersmith M., Richmond M., Spiera H., Peterson M.G., et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 19 (2001) 495-501
8. Hoffman G.S., Cid M.C., Hellmann D.B., Guillevin L., Stone J.H., Schousboe J., et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 46 (2002) 1309-1318
9. Mahr A.D., Jover J.A., Spiera R.F., Hernandez-Garcia C., Fernandez-Gutierrez B., Lavalley M.P., et al. Adjunctive methotrexate for treatment of giant cell arteritis : an individual patient data meta-analysis. Arthritis Rheum 56 (2007) 2789-2797
10. Andonopoulos A.P., Meimaris N., Daoussis D., Bounas A., and Giannopoulos G. Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis. Ann Rheum Dis 62 (2003) 1116
11. Tan A.L., Holdsworth J., Pease C., Emery P., and McGonagle D. Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis 62 (2003) 373-374
12. Ahmed M.M., Mubashir E., Hayat S., Fowler M., and Berney S.M. Treatment of refractory temporal arteritis with adalimumab. Clin Rheumatol 26 (2007) 1353-1355
13. Hoffman G.S., Cid M.C., Rendt-Zagar K.E., Merkel P.A., Weyand C.M., Stone J.H., et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis : a randomized trial. Ann Intern Med 146 (2007) 621-630
14. Martinez-Taboada V.M., Rodriguez-Valverde V., Carreno L., Lopez-Longo J., Figueroa M., Belzunegui J., et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 67 (2008) 625-630
15. Tanaka F., Kawakami A., Iwanaga N., Tamai M., Izumi Y., Aratake K., et al. Infliximab is effective for Takayasu arteritis refractory to glucocorticoid and methotrexate. Intern Med 45 (2006) 313-316
16. Della Rossa A., Tavoni A., Merlini G., Baldini C., Sebastiani M., Lombardi M., et al. Two Takayasu arteritis patients successfully treated with infliximab : a potential disease-modifying agent?. Rheumatology (Oxford) 44 (2005) 1074-1075
17. Hoffman G.S., Merkel P.A., Brasington R.D., Lenschow D.J., and Liang P. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 50 (2004) 2296-2304
18. Molloy E.S., Langford C.A., Clark T.M., Gota C.E., and Hoffman G.S. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis : long-term follow-up. Ann Rheum Dis 67 (2008) 1567-1569
19. Bartolucci P., Ramanoelina J., Cohen P., Mahr A., Godmer P., Le Hello C., et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides : an open pilot study on 10 patients. Rheumatology (Oxford) 41 (2002) 1126-1132
20. Josselin L., Mahr A., Cohen P., Pagnoux C., Guaydier-Souquieres G., Hayem G., et al. Infliximab efficacy and safety against refractory systemic necrotising vasculitides : long-term follow-up of 15 patients. Ann Rheum Dis 67 (2008) 1343-1346
21. Lamprecht P., Voswinkel J., Lilienthal T., Nolle B., Heller M., Gross W.L., et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 41 (2002) 1303-1307
22. Booth A.D., Jefferson H.J., Ayliffe W., Andrews P.A., and Jayne D.R. Safety and efficacy of TNFalpha blockade in relapsing vasculitis. Ann Rheum Dis 61 (2002) 559
23. Stone J.H., Uhlfelder M.L., Hellmann D.B., Crook S., Bedocs N.M., and Hoffman G.S. Etanercept combined with conventional treatment in Wegener's granulomatosis : a six-month open-label trial to evaluate safety. Arthritis Rheum 44 (2001) 1149-1154
24. Guillevin L, Cohen P, Pagnoux C, Mahr A, Cottin V, Buchler M et al. Comparison of Infliximab and Rituximab in Wegener's Granulomatosis (WG) Refractory to Steroids and Immunosuppressants : a Prospective, Randomized Study on 21 Patients. Arthritis Rheum 2008;abstract 1873.
25. Wegener's granulomatosis etanercept trial (WGET) research group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 352 (2005) 351-361
26. Benucci M., Li Gobbi F., Saviola G., and Manfredi M. Improved rheumatoid digital vasculitis in a patient treated with TNFalpha agent blocking (infliximab). Rheumatol Int 28 (2008) 1253-1255
27. Garcia-Porrua C., and Gonzalez-Gay M.A. Successful treatment of refractory mononeuritis multiplex secondary to rheumatoid arthritis with the anti-tumour necrosis factor alpha monoclonal antibody infliximab. Rheumatology (Oxford) 41 (2002) 234-235
28. Unger L., Kayser M., and Nusslein H.G. Successful treatment of severe rheumatoid vasculitis by infliximab. Ann Rheum Dis 62 (2003) 587-588
29. Richter C., Wanke L., Steinmetz J., Reinhold-Keller E., and Gross W.L. Mononeuritis secondary to rheumatoid arthritis responds to etanercept. Rheumatology (Oxford) 39 (2000) 1436-1437
30. Armstrong D.J., McCarron M.T., and Wright G.D. Successful treatment of rheumatoid vasculitis-associated foot-drop with infliximab. J Rheumatol 32 (2005) 759 [author reply 759-60]
31. Thirion L., Picard D., Mejjad O., Courville P., Le Loet X., and Joly P. Vasculite avec ulcérations cutanées au cours de la polyarthrite rhumatoïde : traitement par anti TNF. Ann Dermatol Venereol 133 (2006) 453-455
32. Puechal X., Miceli-Richard C., Mejjad O., Lafforgue P., Marcelli C., Solau-Gervais E., et al. Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis. Ann Rheum Dis 67 (2008) 880-884
33. Munoz-Fernandez S., Hidalgo V., Fernandez-Melon J., Schlincker A., and Martin-Mola E. Effect of infliximab on threatening panuveitis in Behcet's disease. Lancet 358 (2001) 1644
34. Lanthier N., Parc C., Scavennec R., Dhote R., Brezin A.P., and Guillevin L. Infliximab in the treatment of posterior uveitis in Behcet's disease. Long term follow up in four patients. Presse Med 34 (2005) 916-918
35. Abu El-Asrar A.M., Abboud E.B., Aldibhi H., and Al-Arfaj A. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behcet's disease. Int Ophthalmol 26 (2005) 83-92
36. Benitez-del-Castillo J.M., Martinez-de-la-Casa J.M., Pato-Cour E., Mendez-Fernandez R., Lopez-Abad C., Matilla M., et al. Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab). Eye 19 (2005) 841-845
37. Lindstedt E.W., Baarsma G.S., Kuijpers R.W., and van Hagen P.M. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 89 (2005) 533-536
38. Niccoli L., Nannini C., Benucci M., Chindamo D., Cassara E., Salvarani C., et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study. Rheumatology (Oxford) 46 (2007) 1161-1164
39. Sfikakis P.P., Kaklamanis P.H., Elezoglou A., Katsilambros N., Theodossiadis P.G., Papaefthimiou S., et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease. Ann Intern Med 140 (2004) 404-406
40. Tognon S., Graziani G., and Marcolongo R. Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects. Ann N Y Acad Sci 1110 (2007) 474-484
41. Ohno S., Nakamura S., Hori S., Shimakawa M., Kawashima H., Mochizuki M., et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 31 (2004) 1362-1368
42. Accorinti M., Pirraglia M.P., Paroli M.P., Priori R., Conti F., and Pivetti-Pezzi P. Infliximab treatment for ocular and extraocular manifestations of Behcet's disease. Jpn J Ophthalmol 51 (2007) 191-196
43. Pipitone N., Olivieri I., Padula A., D'Angelo S., Nigro A., Zuccoli G., et al. Infliximab for the treatment of Neuro-Behcet's disease: a case series and review of the literature. Arthritis Rheum 59 (2008) 285-290
44. Connolly M., Armstrong J.S., and Buckley D.A. Infliximab treatment for severe orogenital ulceration in Behcet's disease. Br J Dermatol 153 (2005) 1073-1075
45. Haugeberg G., Velken M., and Johnsen V. Successful treatment of genital ulcers with infliximab in Behcet's disease. Ann Rheum Dis 63 (2004) 744-745
46. Sommer A., Altmeyer P., and Kreuter A. A case of mucocutaneous Behcet's disease responding to etanercept. J Am Acad Dermatol 52 (2005) 717-719
47. Melikoglu M., Fresko I., Mat C., Ozyazgan Y., Gogus F., Yurdakul S., et al. Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study. J Rheumatol 32 (2005) 98-105
48. Steinfeld S.D., Demols P., Salmon I., Kiss R., and Appelboom T. Infliximab in patients with primary Sjogren's syndrome: a pilot study. Arthritis Rheum 44 (2001) 2371-2375
49. Steinfeld S.D., Demols P., and Appelboom T. Infliximab in primary Sjogren's syndrome: one-year followup. Arthritis Rheum 46 (2002) 3301-3303
50. Mariette X., Ravaud P., Steinfeld S., Baron G., Goetz J., Hachulla E., et al. Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS). Arthritis Rheum 50 (2004) 1270-1276
51. Sankar V., Brennan M.T., Kok M.R., Leakan R.A., Smith J.A., Manny J., et al. Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 50 (2004) 2240-2245
52. Moutsopoulos N.M., Katsifis G.E., Angelov N., Leakan R.A., Sankar V., Pillemer S., et al. Lack of efficacy of etanercept in Sjogren syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune activation. Ann Rheum Dis 67 (2008) 1437-1443
53. Efthimiou P., Schwartzman S., and Kagen L.J. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis 65 (2006) 1233-1236
54. Iannone F., Scioscia C., Falappone P.C., Covelli M., and Lapadula G. Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol 33 (2006) 1802-1804
55. Dastmalchi M., Grundtman C., Alexanderson H., Mavragani C.P., Einarsdottir H., Helmers S.B., et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 67 (2008) 1670-1677
56. Hengstman G.J., De Bleecker J.L., Feist E., Vissing J., Denton C.P., Manoussakis M.N., et al. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol 59 (2008) 159-163
57. Ideguchi H., Ohno S., Takase K., Hattori H., Kirino Y., Takeno M., et al. Successful treatment of refractory lupus-associated haemophagocytic lymphohistiocytosis with infliximab. Rheumatology (Oxford) 46 (2007) 1621-1622
58. Takahashi N., Naniwa T., and Banno S. Successful use of etanercept in the treatment of acute lupus hemophagocytic syndrome. Mod Rheumatol 18 (2008) 72-75
59. Hayat S.J., Uppal S.S., Narayanan Nampoory M.R., Johny K.V., Gupta R., and Al-Oun M. Safety and efficacy of infliximab in a patient with active WHO class IV lupus nephritis. Clin Rheumatol 26 (2007) 973-975
60. Hayat S.J., and Uppal S.S. Therapeutic efficacy and safety profile of infliximab in active systemic lupus erythematosus. Mod Rheumatol 17 (2007) 174-177
61. Aringer M., Graninger W.B., Steiner G., and Smolen J.S. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 50 (2004) 3161-3169
62. Denton CP, Engelhart M, Tvede N, Wilson H, Khan K, Shiwen X et al. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2008; 0: ard.2008.096123v1.
63. Menon Y., Cucurull E., and Espinoza L.R. Pancytopenia in a patient with scleroderma treated with infliximab. Rheumatology (Oxford) 42 (2003) 1273-1274 author reply 1274
64. Hamaguchi M., Kawahito Y., Ishino H., Yoshida M., and Yoshikawa T. A case report of tumor necrosis factor-alpha antibody-induced thrombocytopenia associated with emerging IgM anticardiolipin antibody in patients with scleroderma overlap/rheumatoid arthritis. Clin Rheumatol 26 (2007) 988-990
65. Allanore Y., Devos-Francois G., Caramella C., Boumier P., Jounieaux V., and Kahan A. Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab. Ann Rheum Dis 65 (2006) 834-835
66. Santos E., Shaunak S., Renowden S.A., and Scolding N.J. Treatment of refractory neurosarcoidosis with infliximab. J Neurol Neurosurg Psychiatry (2008) 10.1136/jnnp.2008.149989
67. Cruz B.A., Reis D.D., and Araujo C.A. Refractory retinal vasculitis due to sarcoidosis successfully treated with infliximab. Rheumatol Int 27 (2007) 1181-1183
68. Haley H., Cantrell W., and Smith K. Infliximab therapy for sarcoidosis (lupus pernio). Br J Dermatol 150 (2004) 146-149
69. Callejas-Rubio J.L., Ortego-Centeno N., Lopez-Perez L., and Benticuaga M.N. Treatment of therapy-resistant sarcoidosis with adalimumab. Clin Rheumatol 25 (2006) 596-597
70. Doty J.D., Mazur J.E., and Judson M.A. Treatment of sarcoidosis with infliximab. Chest 127 (2005) 1064-1071
71. Utz J.P., Limper A.H., Kalra S., Specks U., Scott J.P., Vuk-Pavlovic Z., et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 124 (2003) 177-185
72. Baughman R.P., Drent M., Kavuru M., Judson M.A., Costabel U., du Bois R., et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 174 (2006) 795-802
73. Judson M.A., Baughman R.P., Costabel U., Flavin S., Lo K.H., Kavuru M.S., et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 31 (2008) 1189-1196
74. Kumari R., and Uppal S.S. Prolonged remission in adult-onset Still's disease with etanercept. Clin Rheumatol 25 (2006) 106-108
75. Kuek A., Weerakoon A., Ahmed K., and Ostor A.J. Adult-onset Still's disease and myocarditis: successful treatment with intravenous immunoglobulin and maintenance of remission with etanercept. Rheumatology (Oxford) 46 (2007) 1043-1044
76. Olivieri I., de Stefano G., Padula A., La Gala A., and de Stefano C. Infliximab in a case of early adult-onset Still's disease. Clin Rheumatol 22 (2003) 369-370
77. Kokkinos A., Iliopoulos A., Greka P., Efthymiou A., Katsilambros N., and Sfikakis P.P. Successful treatment of refractory adult-onset Still's disease with infliximab. A prospective, non-comparative series of four patients. Clin Rheumatol 23 (2004) 45-49
78. Kraetsch H.G., Antoni C., Kalden J.R., and Manger B. Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences. Ann Rheum Dis 60 Suppl 3 (2001) iii55-iii57
79. Husni M.E., Maier A.L., Mease P.J., Overman S.S., Fraser P., Gravallese E.M., et al. Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum 46 (2002) 1171-1176
80. Fautrel B., Sibilia J., Mariette X., and Combe B. Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. Ann Rheum Dis 64 (2005) 262-266
81. Elkayam O., Hawkins P.N., Lachmann H., Yaron M., and Caspi D. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum 46 (2002) 2571-2573
82. Kobak S., Oksel F., Kabasakal Y., and Doganavsargil E. Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients. Clin Rheumatol 26 (2007) 2191-2194
83. Drewe E., Huggins M.L., Morgan A.G., Cassidy M.J., and Powell R.J. Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome. Rheumatology (Oxford) 43 (2004) 1405-1408
84. Gottenberg J.E., Merle-Vincent F., Bentaberry F., Allanore Y., Berenbaum F., Fautrel B., et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum 48 (2003) 2019-2024
85. Lamprecht P., Moosig F., Adam-Klages S., Mrowietz U., Csernok E., Kirrstetter M., et al. Small vessel vasculitis and relapsing panniculitis in tumour necrosis factor receptor associated periodic syndrome (TRAPS). Ann Rheum Dis 63 (2004) 1518-1520
86. Weyhreter H., Schwartz M., Kristensen T.D., Valerius N.H., and Paerregaard A. A new mutation causing autosomal dominant periodic fever syndrome in a Danish family. J Pediatr 142 (2003) 191-193
87. Galon J., Aksentijevich I., McDermott M.F., O'Shea J.J., and Kastner D.L. TNFRSF1A mutations and autoinflammatory syndromes. Curr Opin Immunol 12 (2000) 479-486
88. Drewe E., McDermott E.M., Powell P.T., Isaacs J.D., and Powell R.J. Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients. Rheumatology (Oxford) 42 (2003) 235-239
89. Jacobelli S., Andre M., Alexandra J.F., Dode C., and Papo T. Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS). Rheumatology (Oxford) 46 (2007) 1211-1212
90. Simon A., Bodar E.J., van der Hilst J.C., van der Meer J.W., Fiselier T.J., Cuppen M.P., et al. Beneficial response to interleukin 1 receptor antagonist in traps. Am J Med 117 (2004) 208-210
91. Lanfant-Weybel K, Lequerré T, Vittecoq O. Anti-TNF alpha dans le traitement de la polyarthrite rhumatoïde et de la spondylarthrite ankylosante. Presse Med 2009;Sous presse.
92. De Rycke L., Baeten D., Kruithof E., Van den Bosch F., Veys E.M., and De Keyser F. The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. Lupus 14 (2005) 931-937
93. De Bandt M., Sibilia J., Le Loet X., Prouzeau S., Fautrel B., Marcelli C., et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 7 (2005) R545-R551
94. Jonsdottir T., Forslid J., van Vollenhoven A., Harju A., Brannemark S., Klareskog L., et al. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann Rheum Dis 63 (2004) 1075-1078
95. Nosbaum A., Goujon C., Fleury B., Guillot I., Nicolas J.F., and Berard F. Arterial thrombosis with anti-phospholipid antibodies induced by infliximab. Eur J Dermatol 17 (2007) 546-547
96. Mohan N., Edwards E.T., Cupps T.R., Oliverio P.J., Sandberg G., Crayton H., et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 44 (2001) 2862-2869
97. Silburn S., McIvor E., McEntegart A., and Wilson H. Guillain-Barre syndrome in a patient receiving anti-tumour necrosis factor alpha for rheumatoid arthritis: a case report and discussion of literature. Ann Rheum Dis 67 (2008) 575-576
98. Singer O.C., Otto B., Steinmetz H., and Ziemann U. Acute neuropathy with multiple conduction blocks after TNFalpha monoclonal antibody therapy. Neurology 63 (2004) 1754
99. Massara A., Cavazzini L., La Corte R., and Trotta F. Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new "class effect" paradoxical phenomenon. two case reports and literature review. Semin Arthritis Rheum (2009) 10.1016/j.semarthrit.2008.11.003
100. Farah M., Al Rashidi A., Owen D.A., Yoshida E.M., and Reid G.D. Granulomatous hepatitis associated with etanercept therapy. J Rheumatol 35 (2008) 349-351
101. Seton M. Giant cell arteritis in a patient taking etanercept and methotrexate. J Rheumatol 31 (2004) 1467
102. Song I.H., Appel H., Haibel H., Loddenkemper C., Braun J., Sieper J., et al. New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept. J Rheumatol 35 (2008) 532-536
103. Chung E.S., Packer M., Lo K.H., Fasanmade A.A., and Willerson J.T. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107 (2003) 3133-3140